PMH19 THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF ALCOHOL-DEPENDENT PATIENTS IN POLAND

Abstract

The purpose was to estimate financial consequences of naltrexone reimbursement in the treatment of alcohol-dependent patients in Poland. The budget impact analysis was conducted for two-years time horizon from the public payer perspective (National Health Fund) and, additionally, form the patient perspective. The target population consisting of the alcohol-dependent patients, who are treated in dependent treatment centres and are eligible for naltrexone therapy was estimated on the basis of epidemiological data and clinical expert's opinion. In the analysis two scenarios were compared: present, in which none of the drugs supporting psychotherapy in treatment of alcoholism is reimbursed, and new, in which naltrexone is reimbursed within the catalogue of guaranteed health services in the treatment of alcohol-dependent patients. The analysis presents the costs incurred by public payer and by patient associated only with drugs that support psychotherapy in the considered target population. The costs were not discounted. Consumption of resources was estimated on the basis of epidemiological data and recommended duration of pharmacotherapies. The effect of changes of key parameters and assumptions of primary analysis on the results obtained from the perspective of the public payer was examined in the one-way sensitivity analysis. If the reimbursement of naltrexone is introduced, the annual expenses from the budget of National Health Fund would increase by PLN 11.7 million in the first year, and PLN 11.8 million in the second year of reimbursement. On the other hand, from the patient perspective reimbursement of naltrexone will bring significant cost savings which will annually amount to PLN 28.8 million in the first and second year of the refund. Reimbursement of naltrexone in the treatment of alcohol-dependent patients in Poland will bring additional costs incurred by public payer (National Health Fund) and patient's significant cost savings.